From Our Thought Leaders

Pfizer Appoints Dr. Chris Boshoff to Lead Global R&D Strategy, Pursuing Breakthroughs in Oncology and Beyond

Pfizer Inc. (NYSE: PFE) announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025.... Read more

21 November, 2024 | Thursday | News
Merck CEO Belén Garijo Declares Strong Q3 2024 Growth, Reaffirms Path to Profitable 2024 Finish

Net sales up organically by 3.8% to € 5.3 billion EBITDA pre up organically by 16.9% to € 1.6 billion EBITDA pre margin increases to 30.7% Life Science returns to organic sales growth Healthcare deliver... Read more

21 November, 2024 | Thursday | Company results
CEO Adam Levy Announces Record-Breaking Q3 Revenue for NEXGEL with 141% Year-Over-Year Growth to $2.94 Million

NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record third quarter r... Read more

14 November, 2024 | Thursday | Company results
23andMe CEO Anne Wojcicki Announces Major Restructuring with 40% Workforce Reduction and Shift Away from Therapeutics

Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commences strategic alternatives process for all in-house therapeutic programs 23andMe Holding Co. , ... Read more

12 November, 2024 | Tuesday | News

Bio Finance

BioNTech Acquires Biotheus to Strengthen Oncology Pipeline with Bispecific Antibody Asset BNT327/PM8002

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery... Read more

14 November, 2024 | Thursday | News
Lars Fruergaard Jørgensen Announces 21% Surge in Novo Nordisk’s Operating Profit, Driven by Strong Demand for Diabetes and Obesity Treatments

 Financial report for the period 1 January 2024 to 30 September 2024                                                  ... Read more

06 November, 2024 | Wednesday | Company results

Contract Services

Ardena Secures Full GMP Approval for Expanded Nanomedicine Facility in Oss, Netherlands

" Ardena, a leading CDMO, has received full GMP approval for its advanced nanomedicine facility in Oss. This €20 million investment, featuring state-of-the-art cleanrooms and automated manufacturing flows, equips Ardena to deliver high-quality... Read more

20 November, 2024 | Wednesday | News
Abzena Expands Analytical Capabilities with GMP Cell-Based Potency Assays at Cambridge and San Diego Facilities

" Abzena, a leading CDMO/CRO, now offers GMP cell-based potency assays at its UK and US sites, enhancing its support for complex biologics and ADC programs. The expanded analytical toolkit enables faster, reliable data on drug potency, MOA, and stabi... Read more

20 November, 2024 | Wednesday | News

BioPharma Video

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close